<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962232</url>
  </required_header>
  <id_info>
    <org_study_id>LEGFLOW-2015-02</org_study_id>
    <nct_id>NCT02962232</nct_id>
  </id_info>
  <brief_title>A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW</brief_title>
  <official_title>Evaluation the Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter （LEGFLOW）in Treatment of Stenosis or Occlusion in Below The Knee Arteries: A Prospective, Multicenter, Randomized, Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZhuHai Cardionovum Medical Device Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ZhuHai Cardionovum Medical Device Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation
      Catheter (LEGFLOW) compared to the PTA catheter (AMPHIRION DEEP) in treatment of stenosis or
      occlusion in below the knee artery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation
      Catheter (LEGFLOW) compared to the PTA catheter (AMPHIRION DEEP) in treatment of stenosis or
      occlusion inbelow the knee artery.

      This is a prospective, multi-center, randomized, control, opening, superiority designed
      clinical study. Plan to enroll 172 eligible subjects in 15 centers in China, all these
      subjects will be randomized 1:1 to the study group (LEGFLOW OTW group, n=86) and control
      group (AMPHIRION DEEP group, n=86), and accept the treatment of LEGFLOW OTW and AMPHIRION
      DEEP respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion restenosis determined by CTA</measure>
    <time_frame>6 month post procedure</time_frame>
    <description>Restenosis defined as within the ± 5mm range beyond proximal and / or distal of target lesion, the lumen loss is greater than 50% of the reference vessel lumen diameter (RVD) follow-up by CTA.
Target lesion revascularization (TLR): clinical symptoms of peripheral arterial disease recurrence or worsening, and any target lesion re-intervention caused by diameter stenosis ≥50% (confirmed by Doppler ultrasound, DSA or CT angiography).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success rate</measure>
    <time_frame>at 0-30 days</time_frame>
    <description>device success defines as: the device successfully delivered to the target location, inflated, deflated and withdrawn from the treated balloon inflation tube.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation success rate</measure>
    <time_frame>at 0-30 days</time_frame>
    <description>operation success defines as: the blood supply of the target lesion regained after treatment, residual stenosis less than 50% and without flow-limiting dissection (≥type D) occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical success rate</measure>
    <time_frame>at 0-30 days</time_frame>
    <description>clinical success defines as: operation success, and without any postoperative complication before discharge (death, lesions limb amputation, target lesion thrombosis or TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of the Rutherford score</measure>
    <time_frame>in day 0-30, 6th month, 12th month post operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of the life equality by EQ5D</measure>
    <time_frame>in day 0-30, 6th month, 12th month post operation compares to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target limb ulcer healing rate</measure>
    <time_frame>in day 0-30, 6th month, 12th month post operation</time_frame>
    <description>healing or not, if not: improve, no change, or progression;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization rate</measure>
    <time_frame>in day 0-30, 6th month, 12th month post operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target limb upper amputation and lower amputation rate</measure>
    <time_frame>in day 0-30, 6th month, 12th month post operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse event rate including all cause death, target limb upper amputation and target lesion revascularization</measure>
    <time_frame>in day 0-30, 6th month, 12th month post operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>LEGFLOW OTW group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMPHIRION DEEP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel Releasing Peripheral Balloon Dilatation Catheter</intervention_name>
    <description>treatment group</description>
    <arm_group_label>LEGFLOW OTW group</arm_group_label>
    <other_name>LEGFLOW OTW</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA catheter</intervention_name>
    <description>control group</description>
    <arm_group_label>AMPHIRION DEEP group</arm_group_label>
    <other_name>AMPHIRION DEEP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age from 18 to 85 years (include 18 and 85 year);

          -  critical limb ischemia subjects (Rutherford classification from 3 to 6)

          -  expective survival more than 1 year;

          -  can understand the study objective, self willing enrolls and sign the informed
             consent, and accept scheduled followed up at the specific time.

        Angiographic inclusive criteria:

          -  reference vessel diameter 2.0-3.5mm;

          -  stenosis or occlusion in arterial vasculature below the knee shall have distal
             outflow;

          -  target lesion stenosis ≥70% or occlusion, length ≤270mm;

          -  if subject has ipsilateral / contralateral iliac lesions, the iliac lesion shall meet
             all the following criteria:

               -  iliac lesion or occlusion length ≤100mm and

               -  shall be treated earlier than the target lesion and

               -  shall be treated successfully. the successful treatment standard: 1) residual
                  stenosis &lt;30%; 2) without flow limiting dissection 3) without thrombosis,
                  embolism or any other serious adverse events

        Exclusion Criteria:

          -  subjects currently participate in other drugs or medical devices clinical study and
             have not reach the primary endpoint;

          -  childbearing aged women whose pregnancy test before intervention operation is not
             negative, and lactating mothers;

          -  subjects with renal function insufficiency (serum creatinine&gt; 2.5mg / dL or in renal
             dialysis);

          -  subjects have known be allergy or contraindication to the contrast agent, paclitaxel,
             heparin, antiplatelet, anticoagulant or thrombolytic agents;

          -  subjects plan to a major amputation (over metatarsal level);

          -  stroke subjects within 3 months or stroke subjects with severe hemiplegia and aphasia
             associated sequelaes over 3 months before the intervention operation;

          -  subjects with acute myocardial infarction, thrombolytic therapy or angina within 30
             days before the intervention operation;

          -  subjects whose target lesion limb have gangrene (the gangrene range over the
             metatarsophalangeal joint);

          -  target lesion is a stenosis or occlusion that have prior been treated by scaffold
             implantation, DEB, ordinary balloon catheter or bypass graft;

          -  lesions and /or occlusion locate or extend to popliteal artery or below ankle joint;

          -  subjects requiring be intervention in bilateral lower limb;

          -  the stenosis lesion of ipsilateral femoral artery or ipsilateral popliteal artery have
             a diameter stenosis ≥50% untreated before the intervention operation;

          -  ipsilateral femoral artery or ipsilateral popliteal artery has single or adjacent
             lesion length ≥15cm, or ipsilateral femoral artery or ipsilateral popliteal artery has
             multiple lesion and one of these multiple lesion length ≥10cm or occlusion;

          -  - adjacent lesion: 1) interval no more than 30 mm, 2) can be treated as a single
             lesion;

          -  - multiple lesion: 1) interval no more than 30 mm, 2) need to be treated as multiple
             lesion;

          -  the residual stenosis still ≥30%, even when the length &lt;15cm and stenosis ≥50% single
             or adjacent lesion in ipsilateral femoral artery or ipsilateral popliteal artery has
             been treated, or when each lesion length &lt;10cm and stenosis ≥50% multiple lesion in
             ipsilateral femoral artery or ipsilateral popliteal artery has been treated;

          -  DES and /or DEB has been used in the inflow vessel of lesions treatment;

          -  subject has no patency vessel below the ankle artery before the intervention
             operation;

          -  target vessel aneurysm;

          -  acute or subacute thrombosis in target vessel;

          -  angiography shows severe calcification in the target lesion (before contrast injection
             or digital subtraction angiography, intensive annular calcifications that make target
             lesion not expansion and / or a calcification within the target lesion and locate on
             either sides of the vessel wall whose continuous length over than 5cm);

          -  lesions that the guild wire cannot pass through;

          -  subjects need be treated by thrombus endarterectomy, percutaneous transluminal plaque
             circumcision or laser treatment device indicate by intraoperative angiography;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen zhong, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen zhong, professor</last_name>
    <email>chenzhong8658@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo pingfan, professor</last_name>
      <email>13960721962@163.com</email>
    </contact>
    <investigator>
      <last_name>Guo pingfan, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao Zhanxiang, professor</last_name>
    </contact>
    <contact_backup>
      <email>xiaozhanxianghn@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiao Zhanxiang, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shi xiaoming, a. professor</last_name>
      <email>shixiaoming1999@126.com</email>
    </contact>
    <investigator>
      <last_name>Shi xiaoming, a.professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Lei, professor</last_name>
      <email>drleizhang@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhang Lei, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huang jianhua, professor</last_name>
      <email>huangjianhua@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Huang jianhua, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Xiwei, professor</last_name>
      <email>xiwei1092@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhang Xiwei, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhou weimin, professor</last_name>
      <email>drzwm@sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhou weimin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tian Hongyan, professor</last_name>
      <email>tianhhyyxg@163.com</email>
    </contact>
    <investigator>
      <last_name>Tian Hongyan, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao</last_name>
      <email>xgwkzjc@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jichun</last_name>
    </contact_backup>
    <investigator>
      <last_name>Zhao Jichun, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhong Chen</last_name>
      <email>chenzhong8658@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang wangde, professor</last_name>
      <email>drwangde@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhang wangde, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Frendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen xueming, professor</last_name>
      <email>chenxueming04@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Chen xueming, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yongjun, professor</last_name>
      <email>yongjun.li@foxmail.com</email>
    </contact>
    <investigator>
      <last_name>Li Yongjun, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luo Xiaoyun, A. professor</last_name>
      <email>paperWord@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Luo Xiaoyun, A. professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo wei, professor</last_name>
      <email>pla301dml@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Guo wei, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital, Chinese Accadamy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu Chang, professor</last_name>
      <email>changshu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Shu Chang, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhang Lan, professor</last_name>
      <email>lucky200207@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Zhang Lan, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth people's Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang mi'er, professor</last_name>
      <email>jiangme2013@163.com</email>
    </contact>
    <investigator>
      <last_name>Jiang mi'er, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjing Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dai xiangchen, professor</last_name>
      <email>13302165917@163.com</email>
    </contact>
    <investigator>
      <last_name>Dai xiangchen, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting balloon</keyword>
  <keyword>arterial vasculature below the knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

